Table 3.
Clinical factors of responders and non-responders to IVIG therapy in MG patients.
| Clinical factor | Patients received IVIG n = 61 |
Responders n = 48 |
Non-responders n = 13 |
p value* (two-tailed) |
|---|---|---|---|---|
| Gender, male | 28 (25.9%) | 21 (43.8%) | 7 (53.8%) | 0.547 |
| Age, years | 51.36 ± 17.38 | 50.56 ± 18.03 | 54.31 ± 15.03 | 0.495 |
| Course of the disease, months | 4 (1–156) | 5.5 (1–156) | 2 (1–108) | 0.452 |
| Osserman classification | 0.291 | |||
| IIB | 35 (57.4%) | 30 (62.5%) | 5 (38.5%) | |
| III | 9 (14.8%) | 6 (12.5%) | 3 (23.1%) | |
| IV | 17 (27.9%) | 12 (25%) | 5 (38.5%) | |
| ADL score | 10 (3–22) | 10 (3–21) | 13 (6–22) | 0.191 |
| Thymoma | 22 (36.1%) | 18 (37.5%) | 4 (30.8%) | 0.753 |
| Causes of exacerbations | 0.770 | |||
| First manifestation of MG | 18 (28.5%) | 13 (27.1%) | 5 (38.5%) | |
| Idiopathic/unknown | 25 (41.0%) | 20 (41.7%) | 5 (38.5%) | |
| Post-thymectomy | 13 (21.3%) | 11 (22.9%) | 2 (15.4%) | |
| Infection | 2 (3.3%) | 1 (4.2%) | 1 (7.7%) | |
| Childbirth | 1 (1.6%) | 1 (4.2%) | 0 (0.0%) | |
| Reduction of drug dose | 2 (3.3%) | 2 (4.2%) | 0 (0.0%) | |
| AChR antibody positive | 55 (90.2%) | 45 (93.8%) | 10 (76.9%) | 0.105 |
| VNTR3/3 genotype | 57 (93.4%) | 48 (100.0%) | 9 (69.2%) | 0.001 |
Data are presented as number (%), mean ± standard deviation or median (range).
*
p value compared between responders and non-responders.
AChR, acetylcholine receptor; ADL, Activities of Daily Living; IVIG, intravenous immunoglobulin; MG, myasthenia gravis; VNTR, variable number tandem repeat.